Genenta Science S.p.A.: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Apr 21, 2023 and accepted by EDGAR at Apr 21, 2023, 17:21 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | EUR 5.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −EUR 11.0m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −EUR 8.5m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −EUR 0.47 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −EUR 7.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | EUR 27.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | EUR 4.0k | us-gaap:Cash |
| Current assets | At period end2022-12-31 | EUR 31.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | EUR 33.4m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | EUR 2.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2022-12-31 | EUR 31.1m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-12-31 | 18,216,858 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001493152-23-013272. Last ingested by Listed: Nov 2, 2026, 06:07 ET. Listed shows no prices and gives no investment advice.